Certara corrects Q2 2026 call misstatement on divested business's 2025 adjusted EBITDA

Certara, Inc.

Corrected 2025 adjusted EBITDA for divested Regulatory and Medical Writing business: ~$17M including unallocated overhead costs, not excluding.
Excluding unallocated corporate expense that remains with Certara, 2025 adjusted EBITDA is ~$23M.
Misstatement appeared on Aug 4, 2026 earnings call and Q2 2026 presentation; updated presentation posted to ir.certara.com.
Clarification has no impact on previously reported results, year-over-year comparisons, or 2026 Financial Outlook.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.